Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference

LONDON and PALO ALTO, California, February 5 - Silence Therapeutics plc (AIM: SLN) today announced that Philip Haworth,
Ph.D., chief executive officer, will deliver a corporate overview and
business update at the 12th Annual BIO CEO & Investor Conference. The
conference will be held February 8-9, 2010 at the Waldorf-Astoria Hotel in
New York City.

Silence's presentation will take place at 11:00 a.m. Eastern on Monday,
February 8, 2010. The corporate update provided by Dr. Haworth will include
an overview of the company's recent merger with Intradigm Corporation, as
well as details on the company's expanded RNA interference (RNAi) therapeutic
platform and pipeline.

To access a live audio webcast of the presentation, please log on through
a link located on the Presentations page of the Investor Relations section of
Silence's website at
www.silence-therapeutics.com/index.php?option=com_content&task=view&id=88&Itemid=88

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology
company dedicated to the discovery, development and delivery of targeted,
systemic RNA interference (RNAi) therapeutics for the treatment of serious
diseases. The company possesses multiple proprietary siRNA delivery
technology platforms including AtuPLEX, a system that enables the functional
delivery of siRNA molecules to targeted diseased tissues and cells, while
increasing their bioavailability and intracellular uptake. A second,
complementary delivery technology known as PolyTran(TM) offers safe and
effective systemic administration using a library of novel peptide-based
biodegradable polycationic polymers. Additionally, the company has a platform
of novel short interfering RNA (siRNA) molecules, AtuRNAi, which provide a
number of advantages over conventional siRNA molecules, including increased
stability against nuclease degradation. Silence's unique RNAi assets also
include structural features for a next generation of RNAi molecules and
additional proprietary siRNA sequences against more than 50 highly valued
oncology and other disease targets.

Silence has built a strong and diverse intellectual property portfolio
covering all essential areas of RNAi therapeutic development including
multiple proprietary siRNA delivery technologies, potent siRNA sequences and
key siRNA structural and chemical features, as well as specific high-value
disease targets. This portfolio includes an exclusive license to the Zamore
patent family from the University of Massachusetts, which covers broad
structural features of siRNA design for more potent next generation siRNA
sequences.

Silence Therapeutics is headquartered in London, UK, with research and
development operations in Berlin and Palo Alto, CA.

Forward-Looking Statements

This press release includes forward-looking statements that are subject
to risks, uncertainties and other factors. These risks and uncertainties
could cause actual results to differ materially from those referred to in the
forward-looking statements. All forward-looking statements are based on
information currently available to Silence Therapeutics and Silence
Therapeutics assumes no obligation to update any such forward-looking
statements.

Phil Haworth of Silence Therapeutics, +1-650-855-1514, p.haworth at silence-therapeutics.com; or Tim Brons, media, +1-415-675-7400, tbrons at vidacommunication.com, or Stephanie Diaz, investors, +1-415-675-7400, sdiaz at vidacommunication.com, both of Vida Communication for Silence Therapeutics